PeriphaGen's lead product, PGN-503, is designed to prevent or treat peripheral neuropathy in patients receiving chemotherapy. Clinical trials in breast cancer and colorectal cancer will begin soon.
PGN-503 FOR THE PREVENTION and TREATMENT OF CIPN
To see how our PGN-503 can prevent CIPN click here
PeriphaGen's NET platform is capable of expressing a variety of gene products within the nervous system, including the ability to express more than one gene product at once from a single vector. This capability has allowed PeriphaGen to develop several potential drug candidates to address other peripheral nerve disorders including other types of neuropathy and chronic pain. Check back later to learn more about these additional products.